28 Jan , 2026 By : Debdeep Gupta
Caplin Point Laboratories shares gained 2 percent in the opening trade on January 28 after the company received final approval from the United States Food and Drug Administration (USFDA) for its injectable suspension used in anti-inflammatory treatment.
At 09:20am, Caplin Point Laboratories was quoting at Rs 1,765.95, up Rs 37.20, or 2.15 percent, on the BSE.
The company's subsidiary Caplin Steriles has been granted final approval from the USFDA for its abbreviated new drug application (ANDA) methylprednisolone acetate injectable suspension USP, 40mg/mL & 80mg/mL single dose vials, a generic therapeutic equivalent version of the reference listed drug (RLD) DEPO-MEDROL from Pfizer Inc., USA.
The said suspension is primarily used as an anti-inflammatory treatment in various conditions, including in allergic states, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic diseases, ophthalmic diseases, respiratory diseases, rheumatic disorders etc.
A meeting of the board of directors of the company will be held on Thursday, February 05, 2026, to consider and approve, the unaudited financial results of the
company for the quarter and nine months ended December 31, 2025 (both standalone & consolidated).
In the previous trading session, Caplin Point Laboratories shares closed at Rs 1,721.50, down Rs 13.25, or 0.76 percent. The stock has touched a 52-week high of Rs 2,396.95 on September 17, 2025, and a 52-week low of Rs 1,551.05 on April 7, 2025. Currently, the stock is trading 27.85 percent below its 52-week high and 11.51 percent above its 52-week low. The company’s market capitalisation stands at Rs 13,085.41 crore.
On a one-year basis, the share price has declined by more than 22 percent.
0 Comment